Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barwon Health
With
AstraZeneca
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal
Adequately diagnosed and treated Stage I-IIIa early breast cancer
Oestrogen receptor and/or progesterone receptor positive breast cancer
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Hormone replacement therapy (HRT) must be discontinued at least 2 weeks prior to registration
Any prior tamoxifen taken for a total of 8 weeks or less
Any prior anastrozole taken for a total of 4 weeks or less
Anastrozole is clinically indicated to be the best adjuvant strategy
Signed written informed consent
You may not be if
Clinical or radiological evidence of distant spread of disease
Prior treatment with bisphosphonates within the past 12 months
Prior treatment with continuous systemic corticosteroids within the past 12 months
Prior use of parathyroid hormone for more than 1 week
Prior use of systemic sodium fluoride for \> 3 months during the past 2 years
Currently treated with any drugs known to affect the skeleton
Abnormal renal function (serum creatinine greater than or equal to 265.2 mmol/L)
History of diseases with influence on bone metabolism. Patients with lactose intolerance are also excluded
Delayed oesophageal emptying such as stricture or achalasia
Hypersensitivity to alendronate or anastrozole
Previous or concomitant malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix
AST/SGOT and/or ALT/SGPT \> 3 x ULN in combination with other laboratory and clinical abnormalities indicating liver insufficiency
Fracture due to minimal trauma, demonstrated radiologically
Clareo Health | Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
